ArticleAnnals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc2026
Benefits of Implantable Cardioverter-Defibrillator for Secondary Prevention in Patients With Organic Heart Disease.
Article in Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Benefits of Implantable Cardioverter-Defibrillator for Secondary Prevention in Patients With Organic Heart Disease.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImplantable cardioverter-defibrillators (ICD) are first-line treatment to prevent sudden cardiac death due to recurrent ventricular tachycardia and fibrillation (VT/VF). However, some patients with organic heart disease (OHD) die without ever receiving appropriate ICD therapy. This study aimed to identify predictors of death without appropriate ICD therapy in patients with OHD who received ICD or cardiac resynchronization therapy with a defibrillator (CRT-D) for secondary prevention.
methodsWe analyzed consecutive patients who received ICD/CRT-D for secondary prevention between 2000 and 2022. Patients without OHD or those alive without appropriate ICD therapy were excluded. The "no-benefit group" included patients who died or developed severe disability without appropriate ICD therapy or those who died within 1 year after their first appropriate therapy. The "benefit group" included patients who survived > 1 year after appropriate therapy. Clinical characteristics were compared between the groups.
resultsOf the 170 patients analyzed (median follow-up: 9.1 years), 43 (25%) were classified into the no-benefit group (30 died without appropriate therapy, 10 died within 1 year of first appropriate therapy, and 3 developed severe disability without appropriate therapy). Multivariate analyses identified age > 70 years and history of VF as independent predictors of "no benefit." Among patients with VF aged ≥ 70 years, 71% were classified into the no-benefit group.
conclusionsAlthough 75% of patients benefited from ICD therapy for secondary prevention, elderly patients with VF may gain limited benefits from ICD implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.